Sr. Director, Market Access – Payer Value & Access Strategies
AbbottSalary not specified
Not SpecifiedCompensation
Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, HealthcareIndustries
Requirements
- Expertise in assessing and developing market access strategies at national and provincial levels
- Ability to develop pricing and reimbursement strategies across product lifecycles
- Skills in identifying market access risks and opportunities and formulating countermeasures
- Experience leading evidence generation for market access, ensuring quality and recognition
- Capability to provide timely market access policy environment analysis for business planning
Responsibilities
- Assess and develop the whole market access strategy for company portfolios at national and provincial levels
- Develop pricing and reimbursement strategies for all portfolios throughout their lifecycle
- Identify risks and opportunities in market access and develop countermeasures
- Lead local market access evidence generation and ensure evidence quality and recognition in business implementation
- Provide timely market access policy environment analysis for business planning
- Develop, lead, and coordinate strategies for all market access projects (e.g., NRDL, CHI, EAP)
- Generate favorable policy evidence to support market access activities (e.g., reimbursement, hospital listing)
- Develop and lead HTA (Healthcare Technology Assessment) and HE (Health Economics) initiatives for all portfolios in China, including global model adaptation and local project development
- Play an active role in coordinating cross-functional cooperation and embedding market access strategy aligned with business performance
Skills
Market Access Strategy
Pricing Strategy
Reimbursement Strategy
HTA
Health Economics
Policy Analysis
Evidence Generation
NRDL
Cross-Functional Coordination
Strategic Planning
Acadia Pharmaceuticals
Develops therapies for neurological disorders
About Acadia Pharmaceuticals
Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these disorders while also promoting diversity, equity, and inclusion within their operations.
Dallas, TexasHeadquarters
1993Year Founded
$813.4MTotal Funding
ACQUISITIONCompany Stage
Biotechnology, HealthcareIndustries
501-1,000Employees